Skip to main content
Fig. 3 | Cancer & Metabolism

Fig. 3

From: ETV4/ALYREF-mediated glycolytic metabolism through PKM2 enhances resistance to ferroptosis and promotes the development of intrahepatic cholangiocarcinoma

Fig. 3Fig. 3

ALYREF contributes to ICC cell resistance to ferroptosis through PKM2-mediated glycolytic metabolism. (A) High expression level of ALYREF in ICC was analyzed using the TCGA database. (B) The analysis of the survival rate in the presence of ALYREF and PKM2. (C-D) The expression levels of ALYREF and PKM2 were analyzed by RT-qPCR and WB. (E) ICC cell proliferation was assessed by CCK-8 assay. (F) ICC cell proliferation detected by Edu assay (Magnification: ×50, scale bar = 200 μm). (G) ICC cell migration was examined by Transwell assay (Magnification: ×100, scale bar = 100 μm). (H-J) Measurement of GLU, LD, and ATP content in ICC cells. (K) The expression levels of PDK1, LDHA, and GLUT1 assessed by WB. (L) ICC cell proliferation was assessed by CCK-8 assay. (M) Transwell assay was used to evaluate ICC cell migration after Erastin induction (Magnification: ×100, scale bar = 100 μm). (N) FCM was used to measure ICC cell lipid ROS levels. (O) ELISA was used to detect MDA and Fe2+ levels in ICC cells. *<0.05 vs. sh-NC-1; *P < 0.05; **P < 0.01; ***P < 0.001; n = 3

Back to article page